A citation-based method for searching scientific literature

K V S Hari Kumar, Altamash Shaikh, Pitambar Prusty. Diabetes Res Clin Pract 2013
Times Cited: 61







List of co-cited articles
557 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets.
R Ratner, F Whitehouse, M S Fineman, S Strobel, L Shen, D G Maggs, O G Kolterman, C Weyer. Exp Clin Endocrinol Diabetes 2005
40
7



(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Dooseop Kim, Liping Wang, Maria Beconi, George J Eiermann, Michael H Fisher, Huaibing He, Gerard J Hickey, Jennifer E Kowalchick, Barbara Leiting, Kathryn Lyons,[...]. J Med Chem 2005
559
4

A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis.
Jae Min Cho, Hye Won Jang, Hwanju Cheon, Yeon Taek Jeong, Do-Hoon Kim, Yu-Mi Lim, Song-Hyen Choi, Eun-Kyoung Yang, Chang-Yell Shin, Moon Ho Son,[...]. Diabetes Res Clin Pract 2011
40
7



Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells.
Magis Mandapathil, Benedict Hilldorfer, Miroslaw J Szczepanski, Malgorzata Czystowska, Marta Szajnik, Jin Ren, Stephan Lang, Edwin K Jackson, Elieser Gorelik, Theresa L Whiteside. J Biol Chem 2010
262
4

A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients.
Noriko Satoh-Asahara, Yousuke Sasaki, Hiromichi Wada, Mayu Tochiya, Azusa Iguchi, Reiko Nakagawachi, Shinji Odori, Shigeo Kono, Koji Hasegawa, Akira Shimatsu. Metabolism 2013
124
4

Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice.
A D Dobrian, Q Ma, J W Lindsay, K A Leone, K Ma, J Coben, E V Galkina, J L Nadler. Am J Physiol Endocrinol Metab 2011
105
4

CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse.
R Pacheco, J M Martinez-Navio, M Lejeune, N Climent, H Oliva, J M Gatell, T Gallart, J Mallol, C Lluis, R Franco. Proc Natl Acad Sci U S A 2005
165
4

CD26-mediated co-stimulation in human CD8(+) T cells provokes effector function via pro-inflammatory cytokine production.
Ryo Hatano, Kei Ohnuma, Junpei Yamamoto, Nam H Dang, Chikao Morimoto. Immunology 2013
47
6

Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage.
Claude Knauf, Patrice D Cani, Christophe Perrin, Miguel A Iglesias, Jean François Maury, Elodie Bernard, Fadilha Benhamed, Thierry Grémeaux, Daniel J Drucker, C Ronald Kahn,[...]. J Clin Invest 2005
219
4

Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo.
A Steinbrecher, D Reinhold, L Quigley, A Gado, N Tresser, L Izikson, I Born, J Faust, K Neubert, R Martin,[...]. J Immunol 2001
124
4

CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1.
Kei Ohnuma, Tadanori Yamochi, Masahiko Uchiyama, Kunika Nishibashi, Noritada Yoshikawa, Noriaki Shimizu, Satoshi Iwata, Hirotoshi Tanaka, Nam H Dang, Chikao Morimoto. Proc Natl Acad Sci U S A 2004
87
4

Stimulating β-cell regeneration by combining a GPR119 agonist with a DPP-IV inhibitor.
Ansarullah, Yan Lu, Martha Holstein, Brittany DeRuyter, Alex Rabinovitch, Zhiguang Guo. PLoS One 2013
29
10

The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.
Gian Paolo Fadini, Elisa Boscaro, Mattia Albiero, Lisa Menegazzo, Vera Frison, Saula de Kreutzenberg, Carlo Agostini, Antonio Tiengo, Angelo Avogaro. Diabetes Care 2010
250
4



Metformin improves endothelial function in type 1 diabetic subjects: a pilot, placebo-controlled randomized study.
D Pitocco, F Zaccardi, P Tarzia, M Milo, G Scavone, P Rizzo, F Pagliaccia, R Nerla, A Di Franco, A Manto,[...]. Diabetes Obes Metab 2013
42
7

Sitagliptin, a dipeptidyl peptidase-IV inhibitor, improves psoriasis.
Tatsuya Nishioka, Masayuki Shinohara, Noriyasu Tanimoto, Chizuru Kumagai, Kozo Hashimoto. Dermatology 2012
29
10

Sitagliptin for severe psoriasis.
M Lynch, A-M Tobin, T Ahern, D O'Shea, B Kirby. Clin Exp Dermatol 2014
11
27


Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies.
S Bonner-Weir, P A In't Veld, G C Weir. Diabetes Obes Metab 2014
42
7

The biology of incretin hormones.
Daniel J Drucker. Cell Metab 2006
4


The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro.
Søren Bregenholt, Annette Møldrup, Niels Blume, Allan E Karlsen, Birgitte Nissen Friedrichsen, Ditte Tornhave, Lotte Bjerre Knudsen, Jacob S Petersen. Biochem Biophys Res Commun 2005
142
4


One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial.
Mathijs C Bunck, Michaela Diamant, Anja Cornér, Bjorn Eliasson, Jaret L Malloy, Rimma M Shaginian, Wei Deng, David M Kendall, Marja-Riitta Taskinen, Ulf Smith,[...]. Diabetes Care 2009
303
4


Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.
Sten Madsbad, Thure Krarup, Carolyn F Deacon, Jens J Holst. Curr Opin Clin Nutr Metab Care 2008
77
4

Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans.
Michael A Nauck, Guido Kemmeries, Jens J Holst, Juris J Meier. Diabetes 2011
205
4

Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.
Ling Li, Jiantong Shen, Malgorzata M Bala, Jason W Busse, Shanil Ebrahim, Per Olav Vandvik, Lorena P Rios, German Malaga, Evelyn Wong, Zahra Sohani,[...]. BMJ 2014
140
4

Hypoglycemia in diabetes.
Philip E Cryer, Stephen N Davis, Harry Shamoon. Diabetes Care 2003
732
4

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
Thomas Blevins, John Pullman, Jaret Malloy, Ping Yan, Kristin Taylor, Christine Schulteis, Michael Trautmann, Lisa Porter. J Clin Endocrinol Metab 2011
296
4

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.
John B Buse, Michael Nauck, Thomas Forst, Wayne H-H Sheu, Sylvia K Shenouda, Cory R Heilmann, Byron J Hoogwerf, Aijun Gao, Marilyn K Boardman, Mark Fineman,[...]. Lancet 2013
334
4

Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists.
Urd Kielgast, Jens J Holst, Sten Madsbad. Curr Diabetes Rev 2009
37
8

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.
David Zi Cherney, Bruce A Perkins, Nima Soleymanlou, Ronnie Har, Nora Fagan, Odd Erik Johansen, Hans-Juergen Woerle, Maximilian von Eynatten, Uli C Broedl. Cardiovasc Diabetol 2014
287
4

Glucagon-like peptide 1 improved glycemic control in type 1 diabetes.
Margaret T Behme, John Dupré, Thomas J McDonald. BMC Endocr Disord 2003
53
5

Rosiglitazone preserves islet beta-cell function of adult-onset latent autoimmune diabetes in 3 years follow-up study.
Zhifang Yang, Zhiguang Zhou, Xia Li, Gan Huang, Jian Lin. Diabetes Res Clin Pract 2009
38
7

The addition of rosiglitazone to insulin in adolescents with type 1 diabetes and poor glycaemic control: a randomized-controlled trial.
Monique L Stone, Jan L Walker, Donald Chisholm, Maria E Craig, Kim C Donaghue, Patricia Crock, Donald Anderson, Charles F Verge. Pediatr Diabetes 2008
17
17

The effect of rosiglitazone on overweight subjects with type 1 diabetes.
Suzanne M Strowig, Philip Raskin. Diabetes Care 2005
39
7

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
T Vilsbøll, T Krarup, J Sonne, S Madsbad, A Vølund, A G Juul, J J Holst. J Clin Endocrinol Metab 2003
363
4

Glucagon-like peptide 1(GLP-1) in biology and pathology.
Juris J Meier, Michael A Nauck. Diabetes Metab Res Rev 2005
195
4

Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets.
Loredana Farilla, Angela Bulotta, Boaz Hirshberg, Sergio Li Calzi, Nasif Khoury, Houtan Noushmehr, Cristina Bertolotto, Umberto Di Mario, David M Harlan, Riccardo Perfetti. Endocrinology 2003
467
4

Bariatric surgery induces weight loss but does not improve glycemic control in patients with type 1 diabetes.
Matthias Lannoo, Bruno Dillemans, Yves Van Nieuwenhove, Steffen Fieuws, Chantal Mathieu, Pieter Gillard, André D'Hoore, Bart Van Der Schueren. Diabetes Care 2014
25
12

Bariatric surgery and diabetes: Implications of type 1 versus insulin-requiring type 2.
Spyridoula Maraka, Yogish C Kudva, Todd A Kellogg, Maria L Collazo-Clavell, Manpreet S Mundi. Obesity (Silver Spring) 2015
23
13

Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion.
W A Müller, G R Faloona, E Aguilar-Parada, R H Unger. N Engl J Med 1970
577
4




Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.